-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guangxi is planning to build a high-quality biomedical industry development path with the goal of “strengthening the leader, supplementing the chain, gathering clusters, grasping innovation, cultivating brands, and expanding the market” in the region
.
At present, Guangxi's biomedical industry is in the stage of accelerating development.
There are more than 1,000 key biomedical companies, including 10 listed companies including Zhongheng Group, Liuyao Co.
, Ltd.
, Guilin Sanjin, and Rhine Biotechnology
.
In 2021, Guangxi regards the biopharmaceutical industry as one of the 14 key development industries, strives to promote the leapfrog development of the biopharmaceutical industry, and strives to achieve the goal of 100 billion yuan in biopharmaceuticals.
Focusing on the precise investment promotion of the industrial chain, value chain and innovation chain, it has promoted amendments.
A group of enterprises such as the pharmaceutical industry and Daan Chuanggu came to Guangxi for development
.
It is understood that Guangxi has obvious comprehensive advantages in many aspects such as policy, location, and business environment
.
For example, Guangxi is known as the "natural medicine bank", "material resource gene bank" and "hometown of Chinese medicinal materials".
The planting area of medicinal materials accounts for about one-fifth of the country.
It is also an important channel for the import of Chinese medicinal materials from ASEAN countries
.
In terms of policies, Guangxi is a province in the development of the western region, and enterprises can enjoy all the policies for the development of the western region
.
The state has also given personalized support through strategies such as the Guangxi Beibu Gulf Economic Zone, China-ASEAN Free Trade Area, and the Western Land-Sea New Corridor, with a sound policy support system
.
In terms of investing in biomedical industry projects, Guangxi will share policy dividends in terms of land, finance, technology, talents, and market access
.
Now Guangxi is increasing its support for innovation and venture capital
.
Among them, in terms of talent introduction, Guangxi will provide special financial support for the autonomous region's talents based on the talent level, the level of scientific and technological achievements, the transformation stage, etc.
, for the professional talents introduced by the enterprises established in Guangxi
.
In terms of capital security, the autonomous region government's special fund will be used to actively attract social capital and establish a number of venture capital funds that focus on the biomedicine field
.
In terms of market opening, its pharmaceutical products with independent intellectual property rights in the region will be listed in the government procurement and medical insurance catalogs under the same conditions.
.
In order to better develop biomedicine, Guangxi is improving the development environment of biomedical companies through a series of policies and measures such as talent introduction, capital investment, technological research and development, and market access, and attracting and supporting the development of biomedical companies in Guangxi
.
Moreover, Guangxi is actively cooperating closely with industry, university, research and application.
Currently, Guangxi has 6 national innovation platforms, 13 national biomedical industry incubators, 30 autonomous region-level engineering technology research centers, and 28 autonomous region-level key laboratories in the biomedical industry.
, 54 scientific research institutes and 25 colleges and universities involved in the field of biomedicine research
.
In the next step, Guangxi will deepen the investment promotion and follow-up services of the biopharmaceutical industry, attract a group of good international and domestic biopharmaceutical enterprises to settle in, and strive for the concentration of the biopharmaceutical industry, market brand, independent innovation and talents at the end of the "14th Five-Year Plan" period.
Teams and other aspects have formed a certain comparative advantage in the western region
.
The author was informed that, in order to promote the high-quality development of Guangxi's biomedical industry and better transform and upgrade, on September 23, Guangxi successfully signed 25 projects at the investment promotion seminar for the high-quality development of the biomedical industry, with a total planned investment of 24.
8 billion yuan.
.
.
At present, Guangxi's biomedical industry is in the stage of accelerating development.
There are more than 1,000 key biomedical companies, including 10 listed companies including Zhongheng Group, Liuyao Co.
, Ltd.
, Guilin Sanjin, and Rhine Biotechnology
.
In 2021, Guangxi regards the biopharmaceutical industry as one of the 14 key development industries, strives to promote the leapfrog development of the biopharmaceutical industry, and strives to achieve the goal of 100 billion yuan in biopharmaceuticals.
Focusing on the precise investment promotion of the industrial chain, value chain and innovation chain, it has promoted amendments.
A group of enterprises such as the pharmaceutical industry and Daan Chuanggu came to Guangxi for development
.
It is understood that Guangxi has obvious comprehensive advantages in many aspects such as policy, location, and business environment
.
For example, Guangxi is known as the "natural medicine bank", "material resource gene bank" and "hometown of Chinese medicinal materials".
The planting area of medicinal materials accounts for about one-fifth of the country.
It is also an important channel for the import of Chinese medicinal materials from ASEAN countries
.
In terms of policies, Guangxi is a province in the development of the western region, and enterprises can enjoy all the policies for the development of the western region
.
The state has also given personalized support through strategies such as the Guangxi Beibu Gulf Economic Zone, China-ASEAN Free Trade Area, and the Western Land-Sea New Corridor, with a sound policy support system
.
In terms of investing in biomedical industry projects, Guangxi will share policy dividends in terms of land, finance, technology, talents, and market access
.
Now Guangxi is increasing its support for innovation and venture capital
.
Among them, in terms of talent introduction, Guangxi will provide special financial support for the autonomous region's talents based on the talent level, the level of scientific and technological achievements, the transformation stage, etc.
, for the professional talents introduced by the enterprises established in Guangxi
.
In terms of capital security, the autonomous region government's special fund will be used to actively attract social capital and establish a number of venture capital funds that focus on the biomedicine field
.
In terms of market opening, its pharmaceutical products with independent intellectual property rights in the region will be listed in the government procurement and medical insurance catalogs under the same conditions.
.
In order to better develop biomedicine, Guangxi is improving the development environment of biomedical companies through a series of policies and measures such as talent introduction, capital investment, technological research and development, and market access, and attracting and supporting the development of biomedical companies in Guangxi
.
Moreover, Guangxi is actively cooperating closely with industry, university, research and application.
Currently, Guangxi has 6 national innovation platforms, 13 national biomedical industry incubators, 30 autonomous region-level engineering technology research centers, and 28 autonomous region-level key laboratories in the biomedical industry.
, 54 scientific research institutes and 25 colleges and universities involved in the field of biomedicine research
.
In the next step, Guangxi will deepen the investment promotion and follow-up services of the biopharmaceutical industry, attract a group of good international and domestic biopharmaceutical enterprises to settle in, and strive for the concentration of the biopharmaceutical industry, market brand, independent innovation and talents at the end of the "14th Five-Year Plan" period.
Teams and other aspects have formed a certain comparative advantage in the western region
.
The author was informed that, in order to promote the high-quality development of Guangxi's biomedical industry and better transform and upgrade, on September 23, Guangxi successfully signed 25 projects at the investment promotion seminar for the high-quality development of the biomedical industry, with a total planned investment of 24.
8 billion yuan.
.
